Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
EssilorLuxottica S.A. (EL.PA)
Paris, FR
EssilorLuxottica S.A., established in Paris, France, in 1849, is a global enterprise dedicated to the design, production, and distribution of a wide range of ophthalmic products, including corrective lenses, eyewear frames, and sunglasses. The company extends its reach across North America, Europe, Latin America, Asia, Oceania, and Africa. Its operations are structured into five key divisions: Wholesale, Retail, Lenses and Optical Instruments, Equipment, and Sunglasses and Readers. The Wholesale division handles the manufacturing and large-scale distribution of luxury and performance eyewear. Conversely, the Retail segment is responsible for the direct sale of these premium and athletic vision products to consumers. The Lenses and Optical Instruments segment offers an extensive portfolio of advanced lens technologies, including Varilux progressive lenses, Crizal anti-reflective and anti-smudge coatings, Transitions photochromic lenses (featuring the latest Signature Gen 8), Eyezen lenses optimized for digital screen users, and Xperio polarized sun lenses, alongside corrective lens brands under license such as Nikon and Kodak. This segment also provides essential equipment like lens edging and mounting tools for opticians and laboratories, as well as optometry instruments for eye care professionals, educational bodies, military, and other organizations, while also developing digital platforms for online optical sales. The Equipment division supplies sophisticated digital surfacing and lens coating machinery to prescription laboratories, integrated optical networks, and lens manufacturers worldwide. Finally, the Sunglasses and Readers segment focuses on non-prescription eyewear, offering a diverse collection of sunglasses and reading glasses through various owned brands like Foster Grant, Magnivision, and Ryders Eyewear; licensed brands including Reebok, Steve Madden, Marvel, and Disney; and regional labels such as Bolon and Mujosh. EssilorLuxottica maintains a substantial operational network, encompassing 490 prescription laboratories and edging-mounting facilities. The company, initially known as Essilor International Société Anonyme, adopted its current name in October 2018.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.20% | +0.11% | -3.37% | -22.22% | -43.26% | -35.11% | -28.42% | +0.10% | +23.45% | +48.12% | +3,155.58% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 6 | 0 |
| Buy | 13 | 0 |
| Hold | 4 | +1 |
| Sell | 0 | -1 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Instruments & Supplies: +7.9%+7.5% Q4'25: +15.3% (vs Q4'23)
-
EPS growth Medical - Instruments & Supplies: +16.3%-2.9% Q4'25: -3.4% (vs Q4'23)
-
FCF margin FCF growth · Medical - Instruments & Supplies: +27.1%+12.3% Q4'25: +16.0% (vs Q4'23)
-
EBIT margin Medical - Instruments & Supplies: +13.5%+11.8% Q4'25: +9.4% (vs Q4'23)
-
ROIC Medical - Instruments & Supplies: +6.0%+4.9% Q4'25: +8.0% (vs Q4'23)
-
Share dilution Medical - Instruments & Supplies: +0.1%+1.0% Q4'25: +3.6% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Instruments & Supplies: -0.24×2.63× Q4'25: 1.45× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2001 actual |
Dec 2002 actual |
Dec 2003 actual |
Dec 2004 actual |
Dec 2005 actual |
Dec 2006 actual |
Dec 2007 actual |
Dec 2008 actual |
Dec 2009 actual |
Dec 2010 actual |
Dec 2011 actual |
Dec 2012 actual |
Dec 2013 actual |
Dec 2014 actual |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 21 Rev. Ana. 16 EPS Ana. |
Dec 2027 21 Rev. Ana. 16 EPS Ana. |
Dec 2028 17 Rev. Ana. 9 EPS Ana. |
Dec 2029 14 Rev. Ana. 3 EPS Ana. |
Dec 2030 8 Rev. Ana. 3 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
2.07B
est: 2.10B (-1.6%)
|
2.14B
est: 2.19B (-2.3%)
|
2.12B
est: 2.14B (-1.2%)
|
2.26B
est: 2.30B (-1.7%)
|
2.42B
est: 2.45B (-1.2%)
|
2.69B
est: 2.73B (-1.3%)
|
2.91B
est: 2.95B (-1.6%)
|
3.07B
est: 3.12B (-1.6%)
|
3.27B
est: 3.33B (-1.9%)
|
3.89B
est: 3.90B (-0.1%)
|
4.19B
est: 4.25B (-1.5%)
|
4.99B
est: 5.06B (-1.5%)
|
5.07B
est: 5.21B (-2.7%)
|
5.67B
est: 5.77B (-1.6%)
|
6.72B
est: 6.73B (-0.2%)
|
7.12B
est: 7.10B (+0.3%)
|
9.18B
est: 7.49B (+22.7%)
|
10.83B
est: 7.48B (+44.9%)
|
17.39B
est: 17.37B (+0.1%)
|
14.43B
est: 14.53B (-0.7%)
|
19.82B
est: 19.44B (+2.0%)
|
24.49B
est: 24.56B (-0.3%)
|
25.40B
est: 25.83B (-1.7%)
|
26.51B
est: 26.37B (+0.5%)
|
28.49B
est: 28.05B (+1.6%)
|
30.98B
30.35B – 31.89B
+10.5% YoY
|
34.33B
33.03B – 36.93B
+10.8% YoY
|
37.44B
37.34B – 37.54B
+9.1% YoY
|
39.83B
38.65B – 41.97B
+6.4% YoY
|
42.40B
41.15B – 44.69B
+6.5% YoY
|
| EBITDA |
456.61M
est: 316.72M (+44.2%)
|
500.18M
est: 340.05M (+47.1%)
|
514.17M
est: 393.49M (+30.7%)
|
461.28M
est: 459.73M (+0.3%)
|
527.58M
est: 495.49M (+6.5%)
|
603.66M
est: 594.81M (+1.5%)
|
673.14M
est: 632.20M (+6.5%)
|
689.09M
est: 697.34M (-1.2%)
|
730.15M
est: 726.00M (+0.6%)
|
831.10M
est: 840.00M (-1.1%)
|
892.17M
est: 909.82M (-1.9%)
|
1.09B
est: 1.06B (+3.0%)
|
1.12B
est: 1.07B (+5.0%)
|
1.32B
est: 1.17B (+13.6%)
|
1.61B
est: 1.84B (-12.2%)
|
1.71B
est: 1.47B (+16.4%)
|
2.21B
est: 1.48B (+49.7%)
|
2.62B
est: 3.44B (-23.7%)
|
3.82B
est: 2.70B (+41.4%)
|
2.61B
est: 2.87B (-8.9%)
|
4.71B
est: 3.41B (+37.9%)
|
6.10B
est: 3.77B (+61.8%)
|
6.18B
est: 6.22B (-0.7%)
|
6.55B
est: 6.35B (+3.2%)
|
6.47B
est: 6.76B (-4.2%)
|
7.46B
7.31B – 7.68B
+10.5% YoY
|
8.27B
7.96B – 8.90B
+10.8% YoY
|
9.02B
8.99B – 9.04B
+9.1% YoY
|
9.59B
9.31B – 10.11B
+6.4% YoY
|
10.21B
9.91B – 10.76B
+6.5% YoY
|
| EBIT |
310.60M
est: 262.51M (+18.3%)
|
340.58M
est: 298.45M (+14.1%)
|
364.85M
est: 304.53M (+19.8%)
|
351.59M
est: 367.10M (-4.2%)
|
402.92M
est: 399.78M (+0.8%)
|
471.15M
est: 437.48M (+7.7%)
|
533.84M
est: 499.50M (+6.9%)
|
612.97M
est: 534.14M (+14.8%)
|
586.75M
est: 549.11M (+6.9%)
|
651.39M
est: 648.94M (+0.4%)
|
711.48M
est: 674.43M (+5.5%)
|
861.00M
est: 813.35M (+5.9%)
|
865.00M
est: 859.84M (+0.6%)
|
997.00M
est: 933.36M (+6.8%)
|
1.22B
est: 1.45B (-16.1%)
|
1.27B
est: 1.25B (+2.2%)
|
1.35B
est: 1.30B (+3.9%)
|
1.41B
est: 2.70B (-47.9%)
|
1.71B
est: 1.62B (+5.2%)
|
453.00M
est: 1.41B (-67.9%)
|
2.32B
est: 1.68B (+38.3%)
|
3.19B
est: 1.86B (+71.7%)
|
3.23B
est: 3.08B (+5.0%)
|
3.46B
est: 3.14B (+10.0%)
|
3.36B
est: 3.34B (+0.6%)
|
3.69B
3.62B – 3.80B
+10.5% YoY
|
4.09B
3.94B – 4.40B
+10.8% YoY
|
4.46B
4.45B – 4.47B
+9.1% YoY
|
4.75B
4.61B – 5.00B
+6.4% YoY
|
5.05B
4.90B – 5.33B
+6.5% YoY
|
| Net Income |
164.08M
est: 144.06M (+13.9%)
|
199.44M
est: 148.71M (+34.1%)
|
226.06M
est: 174.84M (+29.3%)
|
244.43M
est: 214.68M (+13.9%)
|
287.92M
est: 240.08M (+19.9%)
|
328.73M
est: 318.67M (+3.2%)
|
366.74M
est: 356.17M (+3.0%)
|
382.36M
est: 388.17M (-1.5%)
|
390.69M
est: 407.30M (-4.1%)
|
461.97M
est: 460.69M (+0.3%)
|
505.62M
est: 504.18M (+0.3%)
|
584.00M
est: 602.57M (-3.1%)
|
593.00M
est: 603.54M (-1.7%)
|
929.00M
est: 656.57M (+41.5%)
|
757.00M
est: 1.10B (-31.2%)
|
813.00M
est: 797.33M (+2.0%)
|
789.00M
est: 858.24M (-8.1%)
|
1.08B
est: 2.08B (-48.0%)
|
1.08B
est: 1.25B (-14.1%)
|
85.00M
est: 904.41M (-90.6%)
|
1.45B
est: 1.08B (+34.5%)
|
2.15B
est: 2.34B (-8.0%)
|
2.29B
est: 2.29B (-0.2%)
|
2.36B
est: 3.25B (-27.4%)
|
2.32B
est: 3.24B (-28.6%)
|
3.39B
3.11B – 3.67B
+4.6% YoY
|
3.87B
3.51B – 4.24B
+14.2% YoY
|
4.65B
3.93B – 5.36B
+20.0% YoY
|
4.82B
4.64B – 5.16B
+3.7% YoY
|
4.94B
4.75B – 5.29B
+2.5% YoY
|
| SGA |
—
est: 780.06M (-100.0%)
|
—
est: 795.53M (-100.0%)
|
—
est: 742.60M (-100.0%)
|
495.46M
est: 1.09B (-54.7%)
|
538.71M
est: 1.17B (-53.8%)
|
604.55M
est: 611.80M (-1.2%)
|
642.63M
est: 674.33M (-4.7%)
|
672.27M
est: 701.25M (-4.1%)
|
706.62M
est: 743.17M (-4.9%)
|
859.71M
est: 851.22M (+1.0%)
|
959.69M
est: 961.44M (-0.2%)
|
1.14B
est: 1.17B (-2.6%)
|
1.18B
est: 1.21B (-2.5%)
|
1.41B
est: 1.30B (+7.9%)
|
1.73B
est: 1.67B (+3.7%)
|
1.81B
est: 1.82B (-0.3%)
|
4.14B
est: 1.91B (+116.2%)
|
5.04B
est: 1.48B (+241.2%)
|
8.25B
est: 1.14B (+621.5%)
|
7.05B
est: 1.68B (+319.3%)
|
9.24B
est: 2.00B (+361.4%)
|
11.67B
est: 2.21B (+427.2%)
|
12.05B
est: 12.16B (-0.9%)
|
12.53B
est: 12.42B (+0.9%)
|
13.23B
est: 13.20B (+0.2%)
|
14.59B
14.29B – 15.02B
+10.5% YoY
|
16.16B
15.55B – 17.39B
+10.8% YoY
|
17.63B
17.58B – 17.68B
+9.1% YoY
|
18.75B
18.19B – 19.76B
+6.4% YoY
|
19.96B
19.37B – 21.04B
+6.5% YoY
|
| EPS |
0.72
est: 0.79 (-9.1%)
|
0.91
est: 0.88 (+3.9%)
|
0.99
est: 1.01 (-2.0%)
|
1.21
est: 1.26 (-3.8%)
|
1.41
est: 1.46 (-3.5%)
|
1.61
est: 1.64 (-1.8%)
|
1.78
est: 1.80 (-1.1%)
|
1.85
est: 1.91 (-3.0%)
|
1.89
est: 1.98 (-4.6%)
|
2.20
est: 2.26 (-2.6%)
|
2.44
est: 2.56 (-4.7%)
|
2.80
est: 2.90 (-3.3%)
|
2.82
est: 2.99 (-5.7%)
|
4.41
est: 3.14 (+40.6%)
|
3.57
est: 3.64 (-1.9%)
|
3.79
est: 3.78 (+0.3%)
|
3.58
est: 3.90 (-8.2%)
|
4.15
est: 3.90 (+6.3%)
|
2.48
est: 4.41 (-43.7%)
|
0.20
est: 1.86 (-89.2%)
|
3.30
est: 4.95 (-33.4%)
|
4.87
est: 6.47 (-24.7%)
|
5.11
est: 5.08 (+0.6%)
|
5.20
est: 6.88 (-24.5%)
|
5.04
est: 6.82 (-26.1%)
|
7.30
6.70 – 7.90
+7.0% YoY
|
8.34
7.55 – 9.12
+14.3% YoY
|
9.40
8.46 – 11.54
+12.7% YoY
|
10.38
9.98 – 11.10
+10.4% YoY
|
10.64
10.23 – 11.38
+2.5% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-28 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-27 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-26 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-25 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-22 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-21 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-20 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-19 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-18 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-15 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-14 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-13 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-12 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-11 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-08 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-07 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-06 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-05 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-04 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-30 | B- | 3/5 | 4/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-29 | B- | 3/5 | 4/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-28 | B- | 3/5 | 4/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-27 | B- | 3/5 | 4/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-24 | B- | 3/5 | 4/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-23 | B | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-22 | B | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-21 | B | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-20 | B | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-17 | B | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-16 | B | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-15 | B | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
Owner Earnings
Ownership Overview
No beneficial ownership filings recorded.
Institutional Activity (13F)
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | ATLAS CAPITAL ADVISORS LLC | 645.00 +645.0 (+100.0%) | 204.47M +204.5M (+100.0%) | 0.00% +0.000 pp | 0.02% +0.023 pp | EUR269.90 +0.0% | 1 qtrs NEW |
| 2 | GENERALI INVESTMENTS CEE, INVESTICNI SPOLECNOST, A.S. | 9.4K +— (+0.0%) | 2.98M -65.9K (-2.2%) | 0.00% +0.000 pp | 0.21% -0.022 pp | EUR235.55 +14.6% | 5 qtrs — |
| 3 | STEIGERWALD, GORDON & KOCH INC. | 11.00 +— (+0.0%) | 3.5K -76.0 (-2.1%) | 0.00% +0.000 pp | 0.00% +0.000 pp | EUR276.00 -2.2% | 2 qtrs — |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Francesco Milleri | Non-Independent Chairman & Chief Executive Officer | 8M | male |
| Paul du Saillant | Deputy Chief Executive Officer & Non-Independent Director | 4M | male |
| Giorgio Iannella | Head of Investor Relations | — | — |
| Marco Catalani | Head of Corporate Communications | — | male |
| Stefano Grassi | Chief Financial Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for EL.PA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
